The treatment of phobic anxiety by zimelidine.
Seven patients who were diagnosed as suffering from phobic anxiety were treated with a new antidepressant which causes relatively selective inhibition of serotonin uptake. This compounds, zimelidine, was given for five weeks in doses of up to 300 mg per day. One patient dropped out of the study. Of the remaining six patients all but one made an improvement, which in most cases is thought to have been a drug effect. One patient relapsed some months following treatment and responded again to treatment with zimelidine having failed to respond to other psychotropic drugs.
D001007:Anxiety / Q000188:drug therapy*; D001977:Brompheniramine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D010698:Phobic Disorders / Q000188:drug therapy*; D011569:Psychiatric Status Rating Scales; D011725:Pyridines / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D015031:Zimeldine
D011725:Pyridines; D012702:Serotonin Antagonists; D015031:Zimeldine; D001977:Brompheniramine